Display options
Cite
Aldawsari HM, Ahmed OAA, Alhakamy NA, et al. Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment. Pharmaceutics. 2021;13(6)doi: 10.3390/pharmaceutics13060783.
Aldawsari, H. M., Ahmed, O. A. A., Alhakamy, N. A., Neamatallah, T., Fahmy, U. A., & Badr-Eldin, S. M. (2021). Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment. Pharmaceutics, 13(6), . https://doi.org/10.3390/pharmaceutics13060783
Aldawsari, Hibah M, et al. "Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment." Pharmaceutics vol. 13,6 (2021). doi: https://doi.org/10.3390/pharmaceutics13060783
Aldawsari HM, Ahmed OAA, Alhakamy NA, Neamatallah T, Fahmy UA, Badr-Eldin SM. Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment. Pharmaceutics. 2021 May 24;13(6). doi: 10.3390/pharmaceutics13060783. PMID: 34073780; PMCID: PMC8225169.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2021 May 24;13(6). doi: 10.3390/pharmaceutics13060783.

Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment.

Pharmaceutics

Hibah M Aldawsari, Osama A A Ahmed, Nabil A Alhakamy, Thikryat Neamatallah, Usama A Fahmy, Shaimaa M Badr-Eldin

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  4. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  5. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

PMID: 34073780 PMCID: PMC8225169 DOI: 10.3390/pharmaceutics13060783

Abstract

Raloxifene hydrochloride (RLX), an antiosteoporotic agent, has been utilized for guarding against breast cancer and recently, for the disease management owing to its estrogen antagonist activity. Nevertheless, RLX exhibits poor bioavailability that could be attributed to reduced water solubility and first pass metabolism. To overcome these challenges, this study aimed at formulating and optimizing RLX emulsomes (RLX-EMLs) to enhance the drug antitumor activity. A 4

Keywords: apoptosis; cell cycle analysis; emulsomes; factorial design; mitochondrial membrane potential; raloxifene hydrochloride

References

  1. Toxicol Pathol. 2007 Jun;35(4):495-516 - PubMed
  2. Toxicol Rep. 2017 Aug 01;4:420-426 - PubMed
  3. Nanomedicine (Lond). 2016 Mar;11(6):673-92 - PubMed
  4. Front Bioeng Biotechnol. 2020 Feb 11;8:50 - PubMed
  5. Pharmaceutics. 2020 Jun 27;12(7): - PubMed
  6. J Drug Target. 2007 Apr;15(3):206-17 - PubMed
  7. Nat Rev Cancer. 2002 Sep;2(9):647-56 - PubMed
  8. Pharmaceutics. 2019 Aug 10;11(8): - PubMed
  9. Drug Deliv. 2016 Nov;23(9):3181-3192 - PubMed
  10. Pharmaceutics. 2019 Apr 11;11(4): - PubMed
  11. J Adv Res. 2020 May 01;24:281-290 - PubMed
  12. Curr Pharm Biotechnol. 2015;16(4):392-405 - PubMed
  13. Nat Rev Dis Primers. 2019 Sep 23;5(1):66 - PubMed
  14. Saudi Pharm J. 2017 May;25(4):633-637 - PubMed
  15. Pharmaceutics. 2016 Aug 26;8(3): - PubMed
  16. Int J Oncol. 2016 Jan;48(1):385-98 - PubMed
  17. Arch Pharm Res. 2015 Dec;38(12):2193-200 - PubMed
  18. Saudi Pharm J. 2018 Jan;26(1):64-70 - PubMed
  19. Int J Pharm. 2010 Jun 30;393(1-2):167-75 - PubMed
  20. Nanomaterials (Basel). 2020 Jun 29;10(7): - PubMed
  21. Antioxidants (Basel). 2020 May 13;9(5): - PubMed
  22. Mol Endocrinol. 2008 Feb;22(2):287-303 - PubMed
  23. J Cancer. 2016 Jun 23;7(10):1281-94 - PubMed
  24. Drug Dev Ind Pharm. 2011 Feb;37(2):178-84 - PubMed
  25. Nanomaterials (Basel). 2020 May 31;10(6): - PubMed
  26. Cancer Biol Ther. 2015;16(12):1794-801 - PubMed
  27. AAPS PharmSciTech. 2018 Apr;19(3):1105-1115 - PubMed
  28. Nat Biotechnol. 2015 Sep;33(9):941-51 - PubMed
  29. Int J Pharm. 2015 May 15;485(1-2):329-40 - PubMed
  30. Biochem Biophys Res Commun. 2003 Oct 24;310(3):956-62 - PubMed
  31. Polymers (Basel). 2021 Mar 13;13(6): - PubMed
  32. Pharmaceutics. 2018 May 18;10(2): - PubMed
  33. Biomatter. 2013 Apr-Jun;3(2): - PubMed
  34. Life Sci. 2016 Oct 15;163:38-45 - PubMed
  35. J Liposome Res. 2019 Dec;29(4):383-398 - PubMed
  36. Int J Pharm. 2020 Oct 15;588:119778 - PubMed
  37. Pharmacol Res. 2005 Oct;52(4):334-9 - PubMed
  38. J Pharm Pharmacol. 2006 Mar;58(3):321-6 - PubMed
  39. Oncogene. 2004 Apr 12;23(16):2861-74 - PubMed
  40. Int J Nanomedicine. 2018 Oct 11;13:6325-6335 - PubMed
  41. Int J Pharm. 2009 Oct 1;380(1-2):181-8 - PubMed
  42. Int J Pharm. 2016 Apr 30;503(1-2):127-40 - PubMed
  43. Breast Cancer Res Treat. 2012 Jul;134(2):875-80 - PubMed
  44. Drug Des Devel Ther. 2017 May 25;11:1605-1621 - PubMed
  45. J Liposome Res. 2012 Mar;22(1):62-71 - PubMed
  46. Pharmaceutics. 2018 Oct 18;10(4): - PubMed
  47. Pharmaceutics. 2018 Nov 12;10(4): - PubMed
  48. Colloids Surf B Biointerfaces. 2010 Nov 1;81(1):263-73 - PubMed
  49. Mol Cells. 2015;38(2):138-44 - PubMed
  50. Pharmaceutics. 2018 Jun 28;10(3): - PubMed
  51. Pharmaceutics. 2020 Oct 11;12(10): - PubMed
  52. Pharm Dev Technol. 2019 Mar;24(3):303-313 - PubMed

Publication Types

Grant support